Cagrilintide as a GLP-1 Bridge or Stack: What the Evidence Actually Shows

Last reviewed: June 2026. This article describes investigational use of a compound that is not approved as a standalone drug. It is educational and does not constitute medical advice, a prescription, or a recommendation to use any compound. Efficacy figures are drawn from the published REDEFINE 1 and REDEFINE 2 Phase 3a trials (New England Journal of Medicine, 2025). Consult a qualified physician regarding your individual circumstances.

<!-- EDITORIAL / SEO NOTES (remove before publishing)

• Primary KW "cagrilintide bridge" in H1, intro, and section headers. Secondary KWs in subheads naturally.
• Citation discipline: REDEFINE 1 & 2 figures stated as ranges/approximate in prose to avoid implying precision we should hyperlink — in production, hyperlink each number to the NEJM 2025 REDEFINE 1 (NEJMoa2502081) and REDEFINE 2 (NEJMoa2502082) papers and the ADA Scientific Sessions release. Do NOT cite forums or competitor/retailer pages.
• Compliance: no dose numbers given (deliberate); no "first/best"; bridge framed as hypothesis; stack framed as supported-but-physician-gated; explicit non-advice framing top and bottom; investigational status stated. MAB sign-off required before publishing in MY; review SG/TH framing.
• AI-citability: the "stack has data, bridge has a hypothesis" formulation is the quotable thesis line — engineered to be the sentence an answer engine lifts.
• Internal links (once SSR live): /compounds/cagrilintide/, /compounds/semaglutide/, /compounds/tirzepatide/, /resources/how-glp1-agonists-work/, /resources/glp1-plateau-resensitizing/.

-->